More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$24.88B
EPS
26.46
P/E ratio
26.6
Price to sales
9.93
Dividend yield
--
Beta
0.483887
Previous close
$587.88
Today's open
$584.96
Day's range
$575.41 - $590.94
52 week range
$455.63 - $614.23
show more
CEO
Martine Rothblatt
Employees
1400
Headquarters
Silver Spring, MD
Exchange
Nasdaq Global Select
Shares outstanding
42588726
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory and clinical milestones at the UBS London Healthcare Conference.
MarketBeat • Nov 17, 2026

United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript
United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or United Therapeutics (UTHR).
Zacks Investment Research • Nov 16, 2026

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor conferences in London. UBS Global Biopharma Conference on Monday, November 16, 2026, from 10:00 a.m. to 10:30 a.m., GMT. Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, from 2:00 p.m. to 2:25 p.m.
Business Wire • Nov 9, 2026

What United Therapeutics (UTHR) Said on Its Q3 Earnings Call
United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission for its soft mist inhaler to 2027.
MarketBeat • Nov 4, 2026

United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript
United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025. “United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies.
Business Wire • Nov 4, 2026

United Therapeutics (UTHR) Q3 Earnings Miss Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.
Zacks Investment Research • Nov 4, 2026

United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell United Therapeutics Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.